Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial

Authors: Bruce D. Cheson, Nancy L. Bartlett, Betsy LaPlant, Hun Ju Lee, Ranjana J Advani, Beth Christian, Catherine Diefenbach, Tatyana Feldman, Stephen M. Ansell - The Lancet 2020 cited by 96